'The FDA is not looking for us to exchange our signature for money, which is basically how the beekeepers feel the veterinarians are going to be. The FDA wants us to know what's going on.'

Cripps Christopher

首页> 外文期刊>Journal of the American Veterinary Medical Association >'The FDA is not looking for us to exchange our signature for money, which is basically how the beekeepers feel the veterinarians are going to be. The FDA wants us to know what's going on.'

【24h】

'The FDA is not looking for us to exchange our signature for money, which is basically how the beekeepers feel the veterinarians are going to be. The FDA wants us to know what's going on.'

机译：“ FDA并不希望我们用我们的签名换钱，这基本上就是养蜂人对兽医的感觉。FDA希望我们知道发生了什么。”

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal of the American Veterinary Medical Association》 |2016年第8期|共4页
作者
Cripps Christopher;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类动物医学（兽医学）;
关键词

相似文献

外文文献
中文文献
专利

1. "The FDA is not looking for us to exchange our signature for money, which is basically how the beekeepers feel the veterinarians are going to be. The FDA wants us to know what's going on." [J] . Cripps Christopher Journal of the American Veterinary Medical Association . 2016,第8期

机译：“ FDA并不希望我们用我们的签名换钱，这基本上就是养蜂人对兽医的感觉。FDA希望我们知道发生了什么。”
2. Successful anti-cancer drug targets able to pass FDA review demonstrate the identifiable signature distinct from the signatures of random genes and initially proposed targets [J] . Anatoly L. Mayburd, Inna Golovchikova, and James L. Mulshine Bioinformatics . 2008,第3期

机译：能够通过FDA审查的成功抗癌药物靶标显示了与随机基因和最初提出的靶标不同的可识别标志
3. Fda Warning Letter Cites Forged Signatures [J] . Washington Drug Letter . 2009,第11期

机译：Fda警告信援引伪造签名
4. What to expect when you're not expecting:A veterinarian, producer and feed mill perspective ofan educational FDA audit [C] . Annual Meeting of the American Association of Swine Veterinarians . 2018

机译：当您不期待时会有什么期待：兽医，生产者和饲料厂的透视教育FDA审计
5. An FDA Perspective on the Regulatory Implications of Complex Signatures to Predict Response to Targeted Therapies [O] . Julia A. Beaver, Abraham Tzou, Gideon M. Blumenthal, -1

机译：FDA关于复杂签名的监管含义以预测对靶向疗法的反应的观点
6. Successful anti-cancer drug targets able to pass FDA review demonstrate the identifiable signature distinct from the signatures of random genes and initially proposed targets [O] . A. L. Mayburd, I. Golovchikova, J. L. Mulshine 2007

机译：能够通过FDA审查的成功抗癌药物目标证明了不同于随机基因的签名和最初提出的目标的可识别签名

'The FDA is not looking for us to exchange our signature for money, which is basically how the beekeepers feel the veterinarians are going to be. The FDA wants us to know what's going on.'

著录项

相似文献

相关主题

期刊订阅